Addiction Treatment Company Sees Opportunities Amidst Ongoing Health Crisis

  • Indivior expects ongoing U.S. opioid crisis to drive sales growth
  • 85% of Indivior’s revenue comes from the U.S.
  • Only 25% of adults in need of opioid use disorder treatment received recommended medications
  • U.S. drug overdoses remain above 100,000 for third year in a row
  • Indivior’s main customer is the U.S. government
  • Indivior transferring stock listing to New York from London
  • Indivior sees opportunity in legal cannabis market
  • Sublocade, Indivior’s once-a-month injectable for opioid disorder delivers 54% year-over-year growth

Indivior, an addiction-treatment company, expects ongoing revenue growth due to the U.S. opioid crisis. The company derives 85% of its revenue from the U.S., where only 25% of those in need of opioid use disorder treatment receive recommended medications. With over 100,000 drug overdose deaths annually, Indivior’s main product, Sublocade, a once-a-month injectable for opioid disorder, delivers 54% year-over-year growth. The company is transferring its stock listing to New York to attract more U.S. investors and analysts.

Factuality Level: 7
Factuality Justification: The article provides accurate and objective information about Indivior’s revenue, the opioid crisis in the U.S., and their treatment for cannabis use disorder. However, it includes some personal perspective from the CEO which may be considered as a bias.
Noise Level: 6
Noise Justification: The article provides some relevant information about Indivior’s revenue growth and its focus on opioid dependence treatment, but it also includes speculative statements from the CEO and a brief mention of cannabis use disorder without delving into the broader context or consequences of these issues. The article could benefit from more in-depth analysis and evidence to support claims.
Public Companies: Indivior (INDV)
Key People: Mark Crossley (Chief Executive), Ryan Preblick (Chief Financial Officer)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: U.S. pharmaceutical industry and Indivior stock
Financial Rating Justification: The article discusses the financial performance of addiction-treatment company Indivior, which derives 85% of its revenue from the U.S., and expects continued growth due to the ongoing opioid crisis. It also mentions the company’s plans to transfer its main stock listing to the U.S. for better growth opportunities and attracting more investors.
Presence Of Extreme Event: Yes
Nature Of Extreme Event: Health Crisis
Impact Rating Of The Extreme Event: Severe
Extreme Rating Justification: The article discusses the ongoing opioid crisis in the U.S., which has led to over 100,000 drug overdose deaths per year and affects a significant portion of the population, causing major health risks and economic consequences.

Reported publicly: www.wsj.com